- Home
- BNTX vs GPN Comparison
BNTX vs GPN Comparison
Compare BNTX & GPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTX
- GPN
- Stock Information
- Founded
- BNTX 2008
- GPN 1967
- Country
- BNTX Germany
- GPN United States
- Employees
- BNTX N/A
- GPN N/A
- Industry
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- GPN Business Services
- Sector
- BNTX Health Care
- GPN Consumer Discretionary
- Exchange
- BNTX Nasdaq
- GPN Nasdaq
- Market Cap
- BNTX 28.3B
- GPN 28.5B
- IPO Year
- BNTX 2019
- GPN 2001
- Fundamental
- Price
- BNTX $108.78
- GPN $100.77
- Analyst Decision
- BNTX Strong Buy
- GPN Buy
- Analyst Count
- BNTX 16
- GPN 24
- Target Price
- BNTX $145.28
- GPN $134.33
- AVG Volume (30 Days)
- BNTX 811.0K
- GPN 2.3M
- Earning Date
- BNTX 05-05-2025
- GPN 04-30-2025
- Dividend Yield
- BNTX N/A
- GPN 0.99%
- EPS Growth
- BNTX N/A
- GPN 63.40
- EPS
- BNTX N/A
- GPN 6.16
- Revenue
- BNTX $3,390,698,192.00
- GPN $10,105,894,000.00
- Revenue This Year
- BNTX N/A
- GPN N/A
- Revenue Next Year
- BNTX N/A
- GPN $5.98
- P/E Ratio
- BNTX N/A
- GPN $16.36
- Revenue Growth
- BNTX N/A
- GPN 4.68
- 52 Week Low
- BNTX $76.53
- GPN $91.60
- 52 Week High
- BNTX $131.49
- GPN $140.38
- Technical
- Relative Strength Index (RSI)
- BNTX 42.81
- GPN 38.26
- Support Level
- BNTX $109.47
- GPN $98.96
- Resistance Level
- BNTX $115.10
- GPN $106.07
- Average True Range (ATR)
- BNTX 4.83
- GPN 2.40
- MACD
- BNTX -0.69
- GPN -0.31
- Stochastic Oscillator
- BNTX 17.49
- GPN 30.78
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
About GPN Global Payments Inc.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.